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Background: Multiple neurodegenerative diseases are characterized by the abnormal accumulation of FUS protein
including various subtypes of frontotemporal lobar degeneration with FUS inclusions (FTLD-FUS). These subtypes
include atypical frontotemporal lobar degeneration with ubiquitin-positive inclusions (aFTLD-U), basophilic inclusion
body disease (BIBD) and neuronal intermediate filament inclusion disease (NIFID). Despite considerable overlap,
certain pathologic features including differences in inclusion morphology, the subcellular localization of inclusions,
and the relative paucity of subcortical FUS pathology in aFTLD-U indicate that these three entities represent related
but distinct diseases. In this study, we report the clinical and pathologic features of three cases of aFTLD-U and two
cases of late-onset BIBD with an emphasis on the anatomic distribution of FUS inclusions.
Results: The aFTLD-U cases demonstrated FUS inclusions in cerebral cortex, subcortical grey matter and brainstem
with a predilection for anterior forebrain and rostral brainstem. In contrast, the distribution of FUS pathology in
late-onset BIBD cases demonstrated a predilection for pyramidal and extrapyramidal motor regions with relative
sparing of cerebral cortex and limbic regions.
Conclusions: The topography of FUS pathology in these cases demonstrate the diversity of sporadic FUS inclusion
body diseases and raises the possibility that late-onset motor neuron disease with BIBD neuropathology may
exhibit unique clinical and pathologic features.
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Since the discovery of missense mutations in the fused-
in-sarcoma (FUS) gene that are pathogenic for familial
amyotrophic lateral sclerosis (ALS), a variety of clinically
and pathologically diverse neurodegenerative diseases
have been found to demonstrate FUS-positive inclusions
in central nervous system (CNS) neurons [1-18]. Rare
juvenile and adult onset forms of ALS exhibit basophilic
inclusions which are immunoreactive for FUS protein,
sometimes but not always associated with FUS mutations
[3,4,6-8,10,11,13,14,18]. In addition to ALS, rare forms of
frontotemporal lobar degeneration (FTLD) also exhibit* Correspondence: edward.lee@uphs.upenn.edu
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reproduction in any medium, provided the ortau-negative, TDP-43 negative, FUS-positive inclusions in
the absence of FUS mutations [1,2,5,9,11,14-17]. FTLD is
a general pathologic term for a group of heterogeneous
diseases characterized neuropathologically by progressive
neurodegeneration with a predilection for frontal and tem-
poral lobes and clinically by frontotemporal dementia
(FTD) with or without motor neuron disease (MND). The
current classification of FTLD variants with underlying
FUS pathology combines three entities formerly known as
atypical FTLD with ubiquitinated inclusions (aFTLD-U),
basophilic inclusion body disease (BIBD) and neuronal
intermediate filament inclusion disease (NIFID) into an
umbrella category of FTLD with FUS inclusions now
known as FTLD-FUS [12].
aFTLD-U cases show characteristic tau-negative, TDP-
43-negative and FUS-positive inclusions [9,11,15,17].
aFTLD-U cases are generally sporadic, early-onset, and
present clinically as aggressive forms of behavioral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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toms. Inclusions in aFTLD-U exhibit a variety of morph-
ologies including dystrophic neurites (DN), numerous types
of neuronal cytoplasmic inclusions (NCI), and characteristic
neuronal intranuclear inclusions (NII) [9,11,15,17]. While
aFTLD-U cases may exhibit a few basophilic inclusions in
subcortical regions, BIBD exhibits numerous intraneuronal
basophilic inclusions on hematoxylin and eosin (H&E)
stained sections that are FUS positive [3-6,11,13,14]. In
addition to these basophilic inclusions, FUS immunohisto-
chemistry of BIBD brain tissue reveals FUS-positive NCIs
in a wide anatomic distribution including the neocortex
and hippocampus. NIIs are rare to absent in BIBD and un-
like aFTLD-U and NIFID these rare NIIs do not exhibit
vermiform morphology [11,14]. The clinical phenotype of
BIBD is varied ranging from pure ALS without dementia
(i.e. the aforementioned juvenile- or adult-onset cases of
sporadic ALS with basophilic inclusions) to ALS with de-
mentia to pure FTD. NIFID is a rare disorder with varied
clinical manifestations in which inclusions tend to be eo-
sinophilic and are immunoreactive for class IV neuronal
intermediate filaments and FUS [1,2,5,9,11,16,19].
Recent clinicopathologic series of various FTLD-FUS
cases reported distinct pathologic features of aFTLD-U,
BIBD and NIFID thereby supporting the notion that these
three diseases represent related but distinct pathologic en-
tities [5,9,11]. To further highlight the diversity of FTLD-
FUS subtypes, we report here the clinical and pathologic
findings of three cases of aFTLD-U and two cases of late-
onset BIBD which have not been previously described in
detail. Sampling throughout the neuraxis demonstrated
that the topographic distribution of FUS pathology was
distinct between these few cases aFTLD-U and late-onset
BIBD, suggesting that although they share a common mo-
lecular pathology (i.e. FUS positive inclusions), there is
considerable heterogeneity amongst the sporadic FUS in-
clusion body diseases. Furthermore, the two late-onset
BIBD cases exhibit clinical and pathologic features that
are distinct from most reported cases of BIBD suggesting
that late-onset sporadic ALS with BIBD neuropathology
may represent an extreme example on one end of the
diverse spectrum of sporadic FUS inclusion diseases.
Results
Five cases with FUS neuropathology including three
cases of aFTLD-U and two cases of BIBD were identi-
fied from the greater than 1500 cases in the University of
Pennsylvania CNDR Brain Bank. As summarized in Table 1,
this included three cases of aFTLD-U (designated as cases
F1-3) and two cases of BIBD (designated as cases B1 and
B2). The aFTLD-U patients were clinically diagnosed with
behavioral variant FTD with age of onset between 42 to 47
years. Cases F2 and F3 also exhibited evidence of parkin-
sonism and MND. The BIBD cases B1 and B2 wereclinically diagnosed with amyotrophic lateral sclerosis-plus
syndrome (ALS-plus) with a late age of onset of 65 and 75
years. Case B1 showed no evidence of parkinsonism or cog-
nitive dysfunction but developed diffuse chorea. Case B2
exhibited both parkinsonism and FTD.
Gross and histologic findings
All three aFTLD-U cases showed gross cerebral atrophy
affecting the frontal lobe, temporal lobe, and the caudate
nucleus. Depigmentation of the substantia nigra was
also observed. Histologic examination confirmed the pres-
ence of neurodegeneration most profoundly affecting the
frontal neocortex, orbitofrontal cortex, temporal cortex,
cingulate gyrus, amygdala, hippocampus (with hippocam-
pal sclerosis in cases F1 and F2), parahippocampal gyrus,
basal ganglia (caudate nucleus and globus pallidus) and
substantia nigra. Inclusions were not appreciated on H&E
stained sections aside from a rare nigral basophilic inclu-
sion in case F3.
BIBD showed mild to no gross cerebral atrophy. Histo-
logic examination demonstrated severe loss of spinal
motor neurons. Corticospinal tract degeneration was not
appreciated in case B1 but was severe in case B2. Case
B1 also demonstrated neurodegeneration most pro-
minently affecting the dorsal midbrain, locus ceruleus,
substantia nigra, and globus pallidus. Case B2 showed
mild to no neuronal loss outside of the pyramidal motor
system. In both cases, basophilic to achromatic NCIs
were readily identified on H&E or cresyl violet stained
sections involving multiple brain regions including the
primary motor cortex, ventral spinal cord, inferior olive,
dentate nucleus of the cerebellum, basis pontis, substantia
nigra and globus pallidus (Figure 1 and data not shown).
Immunohistochemical stains for β-amyloid, tau protein,
TDP-43 and α-synuclein together with thioflavin S stains
performed on all five cases excluded other neurodegenera-
tive diseases including AD, FTLD with TDP-43 or tau in-
clusions, and Lewy body disorders. Neurofibrillary tangles
were only observed in cases F2, B1 and B2 corresponding
to Braak stage I, II and III, respectively. Neuritic plaques
were absent in all cases except for rare neuritic plaques in
the cingulate and angular gyri of case B1.
FUS Inclusion morphology
FUS immunohistochemistry was performed on sections
throughout the neuraxis to compare the morphology
and topography of FUS inclusions in aFTLD-U versus
BIBD. As previously described by others, FUS IHC of
the aFTLD-U cases studied here revealed inclusions with
various morphologies. NCIs exhibited morphologies ran-
ging from compact round inclusions (Figure 1A), to
tangle-like inclusions (Figure 1B), larger conglomerate
inclusions (Figure 1C), and crescentic perinuclear aggre-
gates (Figure 1D). Abundant numbers of NIIs could be















F1 bvFTD aFTLD-U 1130 42 48 F
Inappropriate behavior, loss of interests, obsessive
compulsive behaviors, decreased language output,






aFTLD-U 1200 47 56 M
Inappropriate affect with diminished social skills and
aggression, decreased language output. Hyperorality
and compulsive behaviors. Motor exam showed mild
parkinsonism (increased tone and mild bradykinesia).





aFTLD-U 1241 46 51 M
Change in personality with progressive apathy, loss
of interests, disinhibition with inappropriate laughter,
decreased and slow language output, obsessive
compulsive tendencies. Motor exam initially showed
mild rigidity and brisk deep tendon reflexes without
weakness, atrophy or fasiculations. Later developed
Hoffman reflexes and pathologically brisk deep
tendon reflexes in all four extremities, atrophy of






Chorea BIBD 1229 65 72 F
Progressive gait disorder, arm/hand weakness,
muscle atrophy, dysarthria. Subsequent choreaform
movements of head/neck with milder involvement
of limbs/trunk. No cognitive dysfunction. EMG





BIBD 1569 75 78 M
Progressive weakness with parkinsonian gait, tremor
of right hand, micrographia. Logopenic, poor oral
trails, only producing three words beginning with
the letter “f” in one minute, MMSE initially 28/30 with
only one out of three words for delayed recall task.
EMG showed denervation and fibrillations.
Developed muscle atrophy, fasiculations. Died of
neuromuscular respiratory failure.
Lee et al. Acta Neuropathologica Communications 2013, 1:9 Page 3 of 11
http://www.actaneurocomms.org/content/1/1/9identified including characteristic vermiform (Figure 1E)
or circular NIIs (Figure 1F). DNs of various lengths in-
cluding longer DNs with apparent swollen morphology
were also present (Figure 1G). In contrast, FUS inclu-
sions in BIBD were nearly all cytoplasmic and included
annular or crescentic NCIs, compact round NCIs, larger
conglomerate NCIs and occasional tangle-like NCIs
(Figure 1H-M). A single spinal NII was identified in case
B2, while NIIs were not seen in case B1. Inclusions in all
cases did not stain with antibodies that recognize
neurofilament protein, thereby ruling out the possibility
of NIFID (data not shown). However, inclusions in all
cases did stain with antibodies that recognize ubiquitin,
transportin 1, TAF15 and EWS consistent with the ab-
sence of pathogenic FUS mutation (data not shown). Se-
quencing of the FUS gene revealed no pathogenic FUS
mutations in these five cases.
FUS Inclusion topography
To visualize the distribution of FUS inclusions, their
relative abundance was graded on a scale of 0 (absent)
to 3 (severe) in all CNS regions examined here togenerate pseudocolored topographical maps of the bur-
den of FUS pathology in each case (Figure 2). All three
cases of aFTLD-U showed a similar distribution of FUS
pathology with prominent involvement of frontal and
temporal cortex, hippocampus, parahippocampal gyrus,
orbitofrontal cortex, cingulate gyrus, basal ganglia and
midbrain (Figure 2A-C). In contrast, the topography of
the FUS pathology in the two BIBD cases appeared dif-
ferent (Figure 2D-E) with prominent involvement of the
pyramidal motor system (primary motor cortex, spinal
cord) and extrapyramidal motor areas (inferior olive,
basis pontis, substantia nigra, locus ceruleus, red nucleus,
dentate nucleus of the cerebellum, globus pallidus,
striatium, subthalamic nucleus, thalamus). Case B1 showed
limited FUS pathology in neocortical regions (Figure 2D)
while case B2 showed no neocortical FUS pathology
(Figure 2E). Limbic regions including the parahippocampal
gyrus, amygdala and hippocampus exhibited rare to no
FUS pathology. These topographical maps were generated
using a composite score for both NCIs and NIIs. An ana-
lysis of neocortical regions based solely on the density of
NCIs yielded similar results in that the three cases of
Figure 1 Morphology of FUS inclusions in aFTLD-U and late-onset BIBD. Images of representative FUS inclusions from (A-G) aFTLD-U and
(H-M) BIBD cases are shown. FUS IHC of aFTLD-U revealed various aggregates including (A) compact round NCIs in the dentate gyrus of the
hippocampus, (B) tangle-like inclusions in frontal neocortex, (C) a conglomerate aggregate in a substantia nigra neuron, (D) perinuclear crescentic
inclusions in frontal neocortex, (E) numerous vermiform NIIs in the medullary olive nucleus, (F) a ring shaped NII in a cerebellar dentate nucleus
neuron and (G) a swollen DN in the entorhinal cortex. H&E stain of BIBD cases revealed basophilic inclusions including aggregates involving (H)
the cerebellar dentate nucleus and (I) the primary motor cortex. Cresyl violet stain also stained BIBD inclusions including (J) an aggregate within a
spinal motor neuron. FUS immunohistochemistry of BIBD cases revealed NCIs of various morphologies including (K) conglomerate aggregates
within a substantia nigra neuron and round NCIs involving the (L) dentate nucleus of the cerebellum and (M) pontine nuclei. Scale bars for
(A) 20 μm, (B-D, F-G) 10 μm, (E) 50 μm, (H-K) 10 μm and (L-M) 200 μm are shown.
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BIBD cases, and so the difference in FUS inclusion density
was not due to differences in inclusion type or localization
(data not shown). Again, the near absence of NIIs in the
two cases of BIBD contrasted starkly with the NIIs in mul-
tiple brain regions in aFTLD-U.
To further explore the spatial topography of FUS path-
ology and with the caveat that very few cases wereavailable for study, pathology grades for each brain region
were averaged for aFTLD-U or BIBD and values for the
forebrain were plotted from anterior to posterior
(Figure 3A). aFTLD-U demonstrated a gradient of FUS
inclusions with greater pathology involving anterior cere-
brum relative to posterior cerebrum. Notably, this effect
was not only due to the predilection for frontal and tem-
poral cortex or due to the relative sparing of the visual
Figure 2 Topography of FUS inclusions in aFTLD-U and late-onset BIBD. The density of FUS inclusions throughout the brain and spinal cord
were graded on a 3 point scale and then color coded as green (0, absent), green-yellow (0.5+, rare), yellow (1+, mild), orange (2+, moderate) and
red (3+, severe). Pathology grades were used to generate topographical maps for (A-C) aFTLD-U and (D-E) BIBD cases. Brain regions are labeled
as follows: 1 frontal cortex, 2 orbitofrontal cortex, 3 primary motor cortex, 4 primary sensory cortex, 5 superior and middle temporal cortex,
6, parietal cortex, 7 occipital cortex, 8 cingulate gyrus, 9 midbrain, 10 pons, 11, medulla, 12 spinal cord, 13 dentate nucleus, 14 amygdala,
15 entorhinal cortex, 16 anterior striatum, 17 globus pallidus, 18 posterior striatum, 19 thalamus, 20 subthalamic nucleus, 21 substantia nigra,
22 hippocampus, 23 dorsal medulla, 24 inferior olive, 25 cerebellum.
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(caudate, globus pallidus) were more severely affected than
the thalamus. In contrast, BIBD demonstrated a spatially
restricted pattern with the most pathology towards the
center of the anterior-posterior axis (namely the motor
cortex, basal ganglia and thalamus) with relative sparing of
the more anterior and posterior regions of the cerebrum.
To further explore the spatial distribution of FUS
pathology, average pathology scores for the brainstem
and spinal cord were plotted along the rostral to caudal
axis (Figure 3B). aFTLD-U showed a predilection to-
wards FUS pathology in the rostral brainstem with less
FUS pathology caudally. In contrast, BIBD showed uni-
form FUS pathology along the entire rostral to caudal
axis.
Finally, functionally similar brain regions were defined
which relate to the clinical symptoms seen in FTD and
MND, namely limbic regions, cerebral cortex (non-
isocerebral cortex versus neocortex), extrapyramidal motor
regions, and the pyramidal motor system. Average aFTLD-
U versus BIBD FUS pathology scores were determined for
these functionally distinct brain regions to determine
whether aFTLD-U and BIBD exhibits differential involve-
ment of these select anatomic areas (Figure 3C). aFTLD-U
showed the most FUS pathology in limbic regions (amyg-
dala, hippocampus, parahippocampal gyrus, cingulate gyrus
and orbitofrontal cortex), followed by non-isocerebral cor-
tex (allocortex, periallocortex and proisocortex), neocortex,
extrapyramidal motor regions (striatum, globus pallidus,thalamus, midbrain/substantia nigra, pons, locus ceruleus,
dentate nucleus of the cerebellum, medullary olive), and
motor regions (primary motor cortex, ventral spinal cord).
BIBD showed the opposite rank order in terms of FUS
pathology, with greatest involvement of the pyramidal
motor system followed by the extrapyramidal motor re-
gions, neocortex, non-isocerebral cortex, neocortex and
limbic regions.
Discussion
FUS is one of three RNA- and DNA-binding proteins
that comprise the FET protein family [20]. Together
with EWS and TAF15, these FET proteins share struc-
tural similarities including the propensity to aggregate,
and they all are components of fusion oncogenes associ-
ated with sarcomas and leukemias [20-22]. FUS is pre-
dominantly nuclear but does shuttle between the
nucleus and cytoplasm, and is known to bind to a large
number of RNA molecules to regulate mRNA splicing
and stability [23-28]. Mutations in the FUS gene cause
rare forms of ALS (ALS-FUS) in which motor neuron
degeneration is associated with FUS immunoreactive in-
clusions [8,18]. There is heterogeneity of FUS pathology
in ALS-FUS depending either on the type of FUS muta-
tion and/or age of onset, ranging from round basophilic
FUS positive NCIs to tangle-like FUS positive NCIs to-
gether with glial cytoplasmic inclusions [10]. Pathogenic
mutations most often occur within conserved regions of
exon 15 around the area that encodes a nuclear
Figure 3 Neuroanatomic distribution of FUS pathology in aFTLD-U and late-onset BIBD. (A) FUS pathology grades for brain regions were
averaged for aFTLD-U versus BIBD and forebrain regions were plotted from anterior brain regions (mid-frontal and orbitofrontal cortex) to
posterior brain regions (visual cortex). aFTLD-U scores are shown with black squares while BIBD scores are shown with open circles. (B) Average
FUS pathology grades for brainstem and spinal cord regions were plotted from rostral to caudal. Cerebellum scores represent grades from the
dentate nucleus only, and does not reflect the absence of pathology in the cerebellar folia. aFTLD-U scores are shown with black squares while
BIBD scores are shown with open circles. (C) Average FUS pathology grades for various groups of brain regions are shown for aFTLD-U (black
bars) and BIBD (clear bars). Limbic regions included amygdala, hippocampus, parahippocampal gyrus, orbitofrontal cortex and cingulate gyrus.
Nonisocerebral cortex regions included parahippocampal gyrus, cingulate gyrus and orbitofrontal cortex. Neocortical regions included mid-frontal
cortex, superior and inferior temporal cortex, angular gyrus, motor cortex, sensory cortex and visual cortex. Extrapyramidal motor regions included
basal ganglia, thalamus, midbrain including substantia nigra, pons including locus ceruleus, dentate nucleus of the cerebellum and the medullary
inferior olive nucleus. Motor regions included the motor cortex and the ventral spinal cord grey matter. (D) The hypothetical spread of FUS
pathology is shown based on the topography of FUS inclusions which emphasizes the more widespread involvement of the brain in aFTLD-U
with a predilection for anterior forebrain, cerebral cortex and limbic brain regions compared to the pattern of FUS pathology in BIBD which
involves primarily pyramidal and extrapyramidal motor regions with relative sparing of other brain regions. Although speculative, the topographic
distribution of FUS pathology suggests that aFTLD-U and late-onset BIBD exhibit differences in the spread of FUS pathology.
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of FUS to transportin 1, a protein known to facilitate the
shuttling of various RNA-binding proteins including FET
proteins into the nucleus, suggesting that the abnormal
localization of FUS is linked to neurodegeneration [29-33].
There is a known clinical and pathologic overlap be-
tween ALS and FTD, and this overlap is demonstrated
by the fact that various forms of FTLD including aFTLD,
BIBD and NIFID exhibit FUS immunoreactive inclusions
[14-16]. Unlike the inclusions seen in ALS-FUS, the FUS
immunoreactive inclusions in these sporadic forms of
FTLD are also immunoreactive for EWS, TAF15 and
transportin 1 as reported elsewhere [34-37] and as de-
scribed here. The neuropathology of FTLD-FUS is also
heterogeneous but is clearly distinct from ALS-FUS due
to increased diversity of inclusion morphology such as
the presence of vermiform NIIs in aFTLD-U and NIFID,
and a broader anatomic distribution of FUS pathology[10,11]. In addition to being distinct from ALS-FUS, de-
tailed neuropathologic reports indicate that there are
features which may be used to distinguish between the
three FTLD-FUS subtypes, supporting the idea that
aFTLD, BIBD and NIFID are related but distinct entities
[5,9,11]. In particular, the presence of vermiform NIIs in
aFTLD-U and the near absence of NIIs is BIBD appears
to be one feature which can be used to distinguish
aFTLD-U from BIBD [11].
Many neurodegenerative diseases show a stereotyped
neuroanatomic progression of pathology including tau
protein in AD, amyloid plaque pathology in AD and
α-synuclein pathology in Parkinson’s disease (PD) [38-40].
While the number of cases studied worldwide is too small
to make definitive judgments of the pathologic spread of
FUS pathology, the few cases presented here suggest that
the topography of FUS pathology in aFTLD-U is distinct
from the topography of FUS pathology in late-onset BIBD.
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and neocortical regions with a gradual diminution of
pathology along the anterior-posterior and rostral-caudal
axes (Figure 3D). In contrast, late-onset BIBD shows the
most severe FUS pathology in pyramidal and extrapyram-
idal motor regions with FUS pathology involving the
spinal cord, brainstem and deep grey structures, and rela-
tive sparing of neocortex (aside from motor cortex) and
limbic areas (Figure 3D). Although additional cases are in-
evitably required to extend the findings reported here on
these rare forms of FTLD, our findings suggest that there
is a clinical and pathologic spectrum of FUS disease with a
common molecular pathology (i.e. FUS inclusions), but
with rather disparate pathologies both in terms of the sub-
cellular localization and the neuroanatomic distribution of
FUS inclusions.
The clinical manifestations of FUS pathology are varied,
ranging from pure FTD to pure MND [5,9,11,14-17]. The
two BIBD cases presented here were diagnosed with ALS-
plus syndrome in which MND is associated with one or
more clinical phenomena (i.e. dementia, parkinsonism)
that have been considered by some to exclude the diagno-
sis of ALS [41-45]. However, it is now accepted that 10%
of ALS patients manifest clinical features of FTD and up
to 50% have measureable frontotemporal cognitive deficits
[46]. Since reported cases of BIBD represent a spectrum
ranging from pure MND to pure FTD, categorizing all
BIBD cases as a subtype of FTLD-FUS does not seem to
reflect the clinical and pathologic features of BIBD, par-
ticularly given that clinical signs of frontotemporal dys-
function may not be seen and frontal or temporal lobe
degeneration may be absent. Better understanding of the
molecular events underlying inclusion formation, and the
downstream consequences of FUS abnormalities will help
determine the similarities and disparities which define
these heterogeneous diseases.
The three cases of aFTLD-U presented here are simi-
lar to those described by previous clinical and pathologic
case series and reports of aFTLD-U [9,11,15,17]. In con-
trast, the two cases of BIBD presented here are clinically
and pathologically unique. Most reported cases of BIBD
exhibit an earlier onset of disease and a more wide-
spread neuroanatomic distribution of FUS pathology
[3-6,11,13,14]. The largest reported series of BIBD with
FUS pathology included a total of 8 cases with an aver-
age age of onset of 46 years (ranging from 29 to 57) and
an average age of death of 53 years (ranging from 39 to
68) [11,14]. This series included five cases of dementia
(four of which were behavioral variant of FTD), two
cases of ALS without dementia, and one case of progres-
sive supranuclear palsy-like parkinsonism without de-
mentia. These cases, together with nearly all additional
published BIBD cases, exhibit a wide neuroanatomic
distribution of FUS pathology including moderate tonumerous numbers of NCIs in nearly every brain region
analyzed including the frontal cortex and hippocampus.
NIIs were absent to rare, and NCIs exhibited a wide var-
iety of morphologies including crescentic, annular, granu-
lar, round, tangle-like and irregular. In contrast, the two
BIBD cases reported here represent extreme examples in
terms of age of onset (65, 75) and age of death (72, 78).
The predominant clinical phenotype of these two BIBD
cases was that of MND. Although NCI morphology was
similar to that already reported for BIBD, the near absence
of FUS pathology in limbic regions including the hippo-
campus and parahippocampal gyrus, and the relative spar-
ing of cerebral cortex is not typical of BIBD.
Only two additional cases of BIBD without hippocampal
FUS inclusions have been reported, [4,13] and they were
clinically diagnosed with pure ALS without cognitive or
exptrapyramidal features, while also being the two oldest
cases of BIBD in the literature with age of onset at 73 and
75 (age of death of 75 and 79). The first case was reported
as grossly unremarkable with microscopically evident
motor neuron degeneration in association with basophilic
inclusions [4]. FUS immunoreactive inclusions were ob-
served in pyramidal and extrapyramidal motor systems in-
cluding the anterior horn of the spinal cord, substantia
nigra, oculomotor nuclei, red nuclei, inferior olivary nu-
clei, facial nuclei, pontine nuclei, dentate nuclei, hypoglos-
sal nuclei, vestibular nuclei and locus coerulei [4]. The
second case showed no gross evidence of cerebral atrophy,
microscopically evident motor neuron degeneration, histo-
logically evident basophilic inclusions, an absence of NIIs,
and abundant round FUS immunoreactive NCIs involving
the brainstem, spinal cord, thalamus and dentate nucleus
[13]. The anatomic distribution of FUS pathology in these
two late-onset BIBD cases are similar to the two cases
presented here, including the predilection for pyramidal
and extrapyramidal motor regions, the paucity of limbic
and neocortical pathology, and sparing of the hippocam-
pus. Indeed, the two previously reported cases and the
two current cases are the four oldest cases of BIBD in the
literature. Given that only four cases (including the two
presented in the current study) of late-onset BIBD have
been described, it remains to be seen whether old age at
onset is a definite feature of BIBD cases in which FUS
pathology preferentially affects motor regions with relative
sparing of cerebral cortex and limbic structures. The
MND-predominant clinical phenotype and the distribu-
tion of FUS pathology in these four cases of late-onset
BIBD are somewhat similar to the clinicopathologic fea-
tures of ALS-FUS. However, key distinctions between
ALS-FUS and the late-onset cases of BIBD is the generally
earlier onset of ALS-FUS, the absence of FUS mutation
in late-onset BIBD, and the co-aggregation of FUS,
EWS, TAF15 and transportin 1 in late-onset BIBD
[3,6-8,10,18,35-37].
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a limited number of cases. In particular, our analysis in
which pathology scores were averaged according to
histopathologic diagnosis was used as a means to under-
stand the differences between the three cases of aFTLD-
U and the two cases of BIBD reported here. As such, this
analysis may not reflect the diversity or uniqueness of
aFTLD-U and BIBD in general. For example, there is a
possibility of selection bias in that the two cases of BIBD
were phenotypically characterized by motor neuron dis-
ease and therefore may not be representative of BIBD in
general which is phenotypically diverse. BIBD cases with
motor neuron disease tend to show degeneration of
motor systems (as observed in our cases) while BIBD
cases with frontotemporal dementia show severe degen-
eration in the frontal cortex [11,14,47-52]. Although the
density of FUS inclusions does not necessarily correlate
precisely with the degree of neurodegeneration, we ob-
served fewer neocortical FUS inclusions in BIBD com-
pared to aFTLD-U, in contrast with larger case series
which reported more FUS inclusions in the frontal cor-
tex of BIBD relative to aFTLD-U which may reflect the
broader clinical spectrum captured in previous case
series. The clinical and pathologic heterogeneity of BIBD
is remarkable and the two cases of BIBD reported here
appear to represent one end of the spectrum of BIBD.
Clearly, further experience is required to better under-
stand this diversity. However, despite the issues associ-
ated with the low number of cases (representing <0.4%
of the 1500+ cases in the CNDR Brain Bank), our ana-
lysis of these cases serves to highlight the diversity of
FUS inclusion body diseases.
Conclusions
We report here that the morphology and topography of
FUS inclusions in aFTLD-U versus late-onset BIBD ap-
pear to be distinct. The rarity of these cases makes de-
finitive judgment about the spatial topography or the
staging of FUS neuropathology difficult. However, the
spatial topography of AD and PD pathology supports
the notion that inclusions form and progressively spread
in a predictable neuroanatomic sequence. Experimental
evidence has demonstrated that diverse neurodegenera-
tive disease misfolded proteins and the inclusions they
form can be propagated by direct inoculation of
misfolded proteins, apparently via cell to cell transmis-
sion [53-62]. With the exception of prion diseases, this
cell to cell transmission appears not to be infectious, at
least for AD, PD and FTLD-Tau [63], but rather may
regulate the spatial distribution and spread of pathology.
FUS pathology in aFTLD-U and BIBD is topographically
heterogeneous, but largely affects the brain regions
linked to symptomatology, suggesting that the clinical
phenotype in these diseases is dictated in part bydifferential spread of FUS pathology. Although the mo-
lecular basis for the pathologic diversity of sporadic FUS
inclusion body diseases is entirely unknown, the clinical
and pathologic features of the cases presented here sug-
gest that late-onset BIBD may represent a unique or ex-
treme example of sporadic MND within the diverse
spectrum of FUS proteinopathies.
Methods
Clinical data
Brief summaries of the clinical features of each patient
studied here are provided in Table 1.
Neuropathologic analyses
Neuropathologic analysis was performed according to the
standardized procedures of the Center for Neurodegenera-
tive Disease Research (CNDR) Brain Bank at the University
of Pennsylvania as previously described [64]. Briefly, brain
and spinal cord regions were fixed in neutral buffered for-
malin, and 6 μm thick sections were cut from paraffin-
embedded tissue. CNS tissue samples were obtained from
the following regions for study here: mid-frontal cortex,
orbitofrontal cortex, primary motor cortex, primary sen-
sory cortex, superior and middle temporal cortex, parietal
cortex (angular gyrus), occipital (primary visual) cortex, an-
terior cingulate gyrus, amygdala with parahippocampal
gyrus, anterior striatum, posterior striatum with globus
pallidus, thalamus, hippocampus with parahippocampal
gyrus, cerebellum including dentate nucleus, midbrain in-
cluding substantia nigra, pons including locus ceruleus,
medulla including inferior olive and cervical spinal cord.
Thoracic, lumbar and sacral spinal cord was also examined
for BIBD cases.
Closely adjacent series of sections from each CNS region
were stained with hematoxylin and eosin, thioflavin S, and
Kluver-Barrera methods as well as by immunohistochem-
istry (IHC) using standard ABC methods with microwave
antigen retrieval and a mouse monoclonal anti-FUS anti-
body (ProteinTech, Chicago, IL). We also confirmed the
presence of FUS pathology in multiple additional sections
using a rabbit polyclonal anti-FUS antibody (rabbit anti-
FUS, Sigma Aldrich, St. Louis, MO). Microscopic slides
were examined and the extent of FUS pathology was rated
for each region on an ordinate scale (0 absent, 0.5 rare, 1
mild, 2 moderate and 3 severe) using previously described
criteria for FUS pathology [11]. Inclusions were further
characterized by IHC using antibodies specific for ubiqui-
tin (1510, Chemicon, Temecula, CA), transportin 1 (D45,
Sigma), TAF15 (rabbit anti-TAFII68, Bethyl Laboratories)
and EWS (G-5, Santa Cruz Biotechnology, Santa Cruz,
CA). IHC also was performed with additional antibodies
including NAB228 (anti-Aβ), [65] SYN303 (anti-α-
synuclein), phospho409/410-specific anti-TDP43 (1D3),
[66] PHF1 (anti-phospho-tau) and RMO24 (anti-phospho-
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http://www.actaneurocomms.org/content/1/1/9neurofilament-H) to exclude the presence of other neuro-
degenerative diseases including Alzheimer’s disease (AD),
synucleinopathies, FTLD-TDP, FTLD-Tau and NIFID.
Neuropathologic criteria for the diagnosis of BIBD in-
cluded the presence of numerous basophilic inclusions
in a wide neuroanatomic distribution on H&E stained
sections which were immunoreactive for FUS protein.
The diagnosis of aFTLD-U was based on the presence of
ubiquitin and FUS positive inclusions which could not
be seen on H&E sections, and the paucity of basophilic
inclusions on H&E stained sections. No cases of NIFID
were found in the CNDR Brain Bank based on the ab-
sence of at least moderate numbers of neurofilament im-
munoreactive inclusions in cerebral neocortex or limbic
regions.Genetic analyses
DNA was extracted from brain tissue using QIAsymphony
DNA Mini Kit (Qiagen) following the manufacturer’s
protocol. Standard Sanger sequencing was used to evalu-
ate the entire coding region of FUS and adjacent intronic
regions for cases B1 and B2, and mutation hot spot exons
14 and 15 for cases F1-3 (Beckman Coulter Genomics,
Danvers, MA). Primers are available on request. Data were
analyzed using Mutation Surveyor software (Softgenetics,
State College, PA).Consent
The University of Pennsylvania Institutional Review
Board has reviewed the CNDR Neurodegenerative Dis-
ease Autopsy Brain Bank protocols and has confirmed
that these studies do not meet the criteria for human
subjects research because according to 45 CRF § 45.102
(f ), a human subject is defined as a living individual.
However, all patients reported here were pre-consented
for autopsy prior to death including the use of tissues
for scientific study. At time of death, consent for aut-
opsy was reobtained from next-of-kin.
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